The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Lenus Finvest Pvt Ltd
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
On 24th February 2026, the board of Eiko Lifesciences allotted 1,75,000 equity shares and 1,50,000 convertible warrants on a preferential basis to Lenus Finvest Pvt Ltd, a promoter group entity. With this acquisition, Lenus Finvest's equity holding rose from 23,65,472 shares (17.24%) to 25,40,472 shares (17.71% on non-diluted basis, 14.69% on diluted basis). Including the warrants, its total potential holding would be 26,90,472 shares representing 15.56% on a fully diluted basis. The company's total equity share capital increased from 1,37,20,854 to 1,43,45,854 shares as a result of this allotment.
This is a positive signal of promoter group confidence, as the promoter entity is putting fresh capital into the company via a preferential issue rather than selling. The promoter group's aggregate holding remains below 25%, so no further open-market creeping acquisition restrictions kick in. Shareholders should note equity dilution from the preferential issue and the future dilution if warrants are converted.